Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results.

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 billion, a 22% increase year over year. Comirnaty revenue declined by 37% ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company’s adjusted EPS of ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See why I rate PFE stock as a Hold.

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and sending the stock up about 1% in premarket trading.